847805-30-5

Basic information

• Product Name: (S)-6-Hydroxymethyl-morpholin-3-one
• Synonyms: (S)-6-Hydroxymethyl-morpholin-3-one;(6S)-6-(hydroxymethyl)morpholin-3-one;(S)-6-(Hydroxymethyl)Morpholin-3-One(WX640387)
• CAS NO: 847805-30-5
• Molecular Formula: C₅H₉NO₃
• Molecular Weight: 131.12986
• Product Categories: pharmacetical
• Mol File: 847805-30-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 144-146 °C
• Boiling Point: 397.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.98±0.40(Predicted)
• CAS DataBase Reference: (S)-6-Hydroxymethyl-morpholin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-Hydroxymethyl-morpholin-3-one(847805-30-5)
• EPA Substance Registry System: (S)-6-Hydroxymethyl-morpholin-3-one(847805-30-5)

Safety Data

• Hazardous Substances Data: 847805-30-5(Hazardous Substances Data)

Usage

General Description

(S)-6-Hydroxymethyl-morpholin-3-one, also known as Methyl 3-hydroxymethylmorpholino, is a chemical compound with the molecular formula C5H11NO2. It is a derivative of morpholine and is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. (S)-6-Hydroxymethyl-morpholin-3-one is a white solid at room temperature and is soluble in water and ethanol. It has potential applications in the fields of medicine, agriculture, and chemical engineering, making it a versatile and valuable chemical compound for various industrial processes.

Upstream product

• 1374255-92-1 (S)-6-[(trityloxy)methyl]morpholin-3-one 
• 1374255-91-0 (S)-2-bromo-N-[2-hydroxy-3-(trityloxy)propyl]acetamide 
• 847805-29-2 (-)-2-chloro-N-((S)-2,3-dihydroxypropyl)acetamide 

Downstream Products

• 793644-35-6 (R)-6-(aminomethyl)morpholin-3-one 
• 148638-76-0 tert-butyl (2S)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 1137478-34-2 (R)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-37-5 (S)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-38-6 (R)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1168103-91-0 (S)-5-((5-(4-methoxyphenyl)-4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile 
• 1137478-31-9 (R)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 1137478-36-4 (S)-tert-butyl 2-((2-chloro-5-(4-methoxyphenyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 71620-89-8 (S,S)-reboxetine 
• 847805-34-9 (+)-(2S,3S)-2-[α-(2-ethoxyphenoxy)phenylmethyl]morpholine-4-carboxylic acid tert-butyl ester 
• 847805-31-6 (S)-(+)-2-formylmorpholine-4-carboxylic acid tert-butyl ester 
• 847805-32-7 (+)-(2S,3S)-2-[α-hydroxy(phenyl)methyl]morpholine-4-carboxylic acid tert-butyl ester 
• 847805-33-8 (+)-(2S,3R)-2-[α-hydroxy(phenyl)methyl]morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

PIPERAZINES AS ANTI-OBESITY AGENTS

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.